In the news

The FDA reported that LLK TRADING INC. (Linden, NJ) recalled its 200g packages of “Needle Mushrooms” because it has the potential to be contaminated with Listeria monocytogenes. The recalled “Needle Mushrooms” were distributed to Bally Produce Corp., located at 4900 Maspeth Ave, Maspeth, NY 11378, and were sold to DATANG SUPERMARKET INC. The product comes in a 200 gram, clear plastic packaging on the top and blue (non-transparent) on the bottom. No illnesses have been reported to date in connection with this problem. The potential for contamination was noted after routine testing by the FDA revealed the presence of Listeria monocytogenes in the package they sampled. Vending of the product has been suspended while the FDA and the company continue their investigation into the source of the contamination. @ https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/llk-trading-inc-recalls-needle-mushrooms-because-possible-health-risk

The FDA reported that Wiet Peeters Farm Products Limited (Charing Cross, Ontario, Canada) recalled its Aunt Mid’s Fresh Sliced Mushrooms 227g, Peeters Mushroom Farm Cremini Sliced 227g, and Peeters Mushroom Farm Thick Slice Mushroom 10lb cardboard because they have the potential to be contaminated with Listeria monocytogenes. The recalled mushrooms were distributed in Michigan and Ohio. The recalled products include: (i) Aunt Mid’s Fresh Sliced Mushrooms comes in a 227g flat blue plastic package and BEST BEFORE 25JL04; (ii) Peeters Mushroom Farm Cremini Sliced comes in a 227g flat black plastic package and BEST BEFORE 25JL04; and (iii) Peeters Mushroom Farm Thick Slice Mushroom 10lb cardboard comes in a 10lb cardboard labeled with Peeters Mushroom Farm on the cardboard box. No illnesses have been reported to date in connection with this problem. The potential for contamination was noted after testing by the Canadian FSA revealed the presence of Listeria monocytogenes in 227g packages of Fresh Sliced Mushrooms. The other products affected in this recall have been manufactured on the same line as the 227g fresh sliced mushrooms. @ https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/wiet-peeters-farm-products-limited-recalls-aunt-mids-fresh-sliced-mushrooms-peeters-mushroom-farm

On June 6, 2025, August Egg Company recalled eggs due to Salmonella. The recalled eggs were organic eggs supplied by August Egg Company (Hilmar, California). The CDC, public health and regulatory officials in several states, and the U.S. FDA collected data to investigate a multistate outbreak of Salmonella Enteritidis infections. Currently, the recalled eggs are no longer available for sale and are outside their shelf life. The outbreak caused 134 infections, 38 hospitalizations, and one death. Illnesses were confirmed in 10 states: Arizona, California, Colorado, Kansas, Kentucky, Nebraska, New Jersey, Nevada, Utah, and Washington. WGS showed that Salmonella from sick people’s samples are closely related genetically. Suggesting that people in this outbreak got sick from the same food. The FDA inspected cage-free laying houses used by August Egg Company and collected samples for testing. Three samples tested positive for Salmonella. WGS showed that the Salmonella in the samples matched Salmonella from sick people. The FDA conducted a traceback investigation based on where the ill people reported shopping or eating during the timeframe of interest. August Egg Company was identified as a common supplier of eggs. @ https://www.cdc.gov/salmonella/outbreaks/eggs-06-25/investigation.html

The FDA published more than 200 decision letters, known as Complete Response Letters (CRLs), on July 10, 2025. The CRLs were issued in response to applications submitted to the FDA for approval of drugs or biological products between 2020 and 2024, marking a significant step in the Agency’s broader initiatives to modernize and increase transparency. By making the CRLs available, the public now has significantly greater insight into the FDA’s decision-making and the most common deficiencies cited that sponsors must address before their application is approved. The FDA issues CRLs for various reasons, most related to safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues. Marty Makary, M.D., M.P.H., said that “For far too long, drug developers have been playing a guessing game when navigating the FDA; today, the FDA is bringing meaningful treatments to patients faster.” The CRLs were redacted for trade secrets and confidential commercial information. The Agency is in the process of publishing additional CRLs from its archives and continually exploring ways to provide the public with greater transparency into its decision-making process. @ https://www.fda.gov/news-events/press-announcements/fda-embraces-radical-transparency-publishing-complete-response-letters?utm_medium=email&utm_source=govdelivery